These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30948156)

  • 1. Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions.
    Matsubara H; Niwa A; Nakahata T; Saito MK
    Biochem Biophys Res Commun; 2019 Jul; 515(1):1-8. PubMed ID: 30948156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Natural Killer Cells Differentiated from Various Pluripotent Stem Cells.
    Han J; Son H; Jung D; Kim KY; Jin C; Hwang H; Kang SS; Mitalipov S; An HJ; Lee Y; Kang E
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
    Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
    Lupo KB; Moon JI; Chambers AM; Matosevic S
    Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells.
    Mesquitta WT; Wandsnider M; Kang H; Thomson J; Moskvin O; Suknuntha K; Slukvin II
    Sci Rep; 2019 Apr; 9(1):6622. PubMed ID: 31036928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
    Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
    Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
    Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS
    Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal Expression of Transcription Factor
    Jung J; Chang Y; Jin G; Lian X; Bao X
    ACS Synth Biol; 2022 Jun; 11(6):2001-2008. PubMed ID: 35608547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascorbic acid promotes proliferation of natural killer cell populations in culture systems applicable for natural killer cell therapy.
    Huijskens MJ; Walczak M; Sarkar S; Atrafi F; Senden-Gijsbers BL; Tilanus MG; Bos GM; Wieten L; Germeraad WT
    Cytotherapy; 2015 May; 17(5):613-20. PubMed ID: 25747742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cells differentiated in vitro from cord blood CD34
    Domogala A; Blundell M; Thrasher A; Lowdell MW; Madrigal JA; Saudemont A
    Cytotherapy; 2017 Jun; 19(6):710-720. PubMed ID: 28428057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
    Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
    Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of antileukemia effects of allogeneic NK cells.
    Leung W; Iyengar R; Turner V; Lang P; Bader P; Conn P; Niethammer D; Handgretinger R
    J Immunol; 2004 Jan; 172(1):644-50. PubMed ID: 14688377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.
    van Ostaijen-ten Dam MM; Prins HJ; Boerman GH; Vervat C; Pende D; Putter H; Lankester A; van Tol MJ; Zwaginga JJ; Schilham MW
    J Immunother; 2016; 39(2):90-100. PubMed ID: 26849078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.